SAGA Diagnostics to Present Data on Pathlight MRD Test at ASCO 2026
SAGA Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, is set to present data on its Pathlight MRD test at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago. The company will showcase three abstracts that highlight the effectiveness of its tumor-informed structural variant-based circulating tumor DNA (ctDNA) platform. The presentations will cover ctDNA kinetics in metastatic breast cancer and the use of Pathlight in colon and rectal cancer, focusing on ctDNA clearance, recurrence risk, and outcomes in localized disease. The data underscores Pathlight's potential in treatment monitoring and disease surveillance across various cancer types. 
